RESUMEN

The adrenergic receptors play a key role in the modulation of sympathetic nervous system activity as well as a site of action for many therapeutic agents. The alpha1-adrenergic receptor subtypes (alpha1A-, alpha1B-, alpha1D) are the prime mediators of smooth muscle contraction and hypertrophic growth, but their characterization in both binding and function have lagged the other adrenergic family members. Although they are derived from a related ancestral gene and all nine adrenergic receptor family members bind the endogenous ligands, epinephrine and norepinephrine, with roughly similar affinities, there are major differences in the mode of binding, second messenger utilization, and physiological effects of the alpha1-subtypes compared with beta- or alpha2-subtypes. Here, we review the recent literature on aspects of its binding pocket and how it differs from the beta-adrenergic receptor paradigms. We also review the signaling components and aspects of its function and provide new insights into its roles in smooth muscle, growth, neurological, and cardiovascular function.

Asunto(s)

Receptores Adrenérgicos alfa 1/fisiología , Antagonistas Adrenérgicos alfa/metabolismo , Animales , Humanos , Receptores Adrenérgicos alfa 1/química , Receptores Adrenérgicos alfa 1/clasificación , Receptores Adrenérgicos alfa 1/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología

RESUMEN

alpha(1)-Adrenergic receptors (alpha(1A), alpha(1B), and alpha(1D)) are regulators of systemic arterial blood pressure and blood flow. Whereas vasoconstrictory action of the alpha(1A) and alpha(1D) subtypes is thought to be mainly responsible for this activity, the role of the alpha(1B)-adrenergic receptor (alpha(1B)AR) in this process is controversial. We have generated transgenic mice that overexpress either wild type or constitutively active alpha(1B)ARs. Transgenic expression was under the control of the isogenic promoter, thus assuring appropriate developmental and tissue-specific expression. Cardiovascular phenotypes displayed by transgenic mice included myocardial hypertrophy and hypotension. Indicative of cardiac hypertrophy, transgenic mice displayed an increased heart to body weight ratio, which was confirmed by the echocardiographic finding of an increased thickness of the interventricular septum and posterior wall. Functional deficits included an increased isovolumetric relaxation time, a decreased heart rate, and cardiac output. Transgenic mice were hypotensive and exhibited a decreased pressor response. Vasoconstrictory regulation by alpha(1B)AR was absent as shown by the lack of phenylephrine-induced contractile differences between ex vivo mesenteric artery preparations. Plasma epinephrine, norepinephrine, and cortisol levels were also reduced in transgenic mice, suggesting a loss of sympathetic nerve activity. Reduced catecholamine levels together with basal hypotension, bradycardia, reproductive problems, and weight loss suggest autonomic failure, a phenotype that is consistent with the multiple system atrophy-like neurodegeneration that has been reported previously in these mice. These results also suggest that this receptor subtype is not involved in the classic vasoconstrictory action of alpha(1)ARs that is important in systemic regulation of blood pressure.

Asunto(s)

Cardiomegalia/genética , Hipotensión/genética , Receptores Adrenérgicos alfa 1/biosíntesis , Receptores Adrenérgicos alfa 1/genética , Animales , Presión Sanguínea/genética , Peso Corporal , Bradicardia/genética , Relación Dosis-Respuesta a Droga , Ecocardiografía , Epinefrina/sangre , Arteria Femoral/patología , Frecuencia Cardíaca , Tabiques Cardíacos/patología , Humanos , Hidrocortisona/sangre , Inositol 1,4,5-Trifosfato/biosíntesis , Riñón/metabolismo , Masculino , Ratones , Ratones Noqueados , Ratones Transgénicos , Norepinefrina/sangre , Técnicas de Cultivo de Órganos , Tamaño de los Órganos , Fenotipo , Fenilefrina/sangre , Regiones Promotoras Genéticas , Factores de Tiempo

RESUMEN

The regulation of the cellular distribution and intracellular signaling properties of the alpha(1B)- and alpha(1D)- adrenoceptor (alpha(1)-AR) subtypes was examined in stably transfected Rat 1 fibroblasts. In unstimulated cells, alpha(1B)-AR expression was noted primarily on the cell surface. Treatment with phenylephrine induced internalization of the alpha(1B)-AR and promoted association with arrestin 2. The internalized alpha(1B)-AR colocalized with the transferrin receptor, an endosomal marker. In unstimulated fibroblasts, the alpha(1D)-AR was detected in a perinuclear orientation and was colocalized with arrestin 2 in a compartment also containing the transferrin receptor. After treatment with prazosin, which exhibits inverse agonist properties, the alpha(1D)-AR was redistributed from intracellular sites to the cellular periphery and was no longer associated with the transferrin receptor or arrestin 2. alpha(1D)-AR-expressing cells exhibited a high degree of basal activity for both inositol phosphate formation and extracellular signal regulated kinase (ERK), which was reduced by treatment with prazosin. In these cells, phenylephrine induced a dose-dependent increase in inositol phosphate formation but had no effect on ERK activity. In alpha(1B) -AR-expressing cells, phenylephrine stimulated both inositol phosphate formation and ERK activity. These data show that: 1) there are differences in the cellular localization of the alpha(1)-AR subtypes; 2) the alpha(1B)-AR exhibits expected G protein-coupled receptor activity regarding cellular localization, agonist-mediated internalization, and coupling to second messengers; and 3) the alpha(1D)-AR is constitutively active and, as a result, is localized to intracellular compartments involved in receptor recycling.

Asunto(s)

Agonistas Adrenérgicos/farmacología , Agonistas de Receptores Adrenérgicos alfa 1 , Transducción de Señal , Antagonistas Adrenérgicos/farmacología , Antagonistas de Receptores Adrenérgicos alfa 1 , Animales , Células Cultivadas , Humanos , Inmunohistoquímica , Fosfatos de Inositol , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Ratas , Receptores Adrenérgicos alfa 1/metabolismo , Receptores de Superficie Celular/metabolismo , Transfección

RESUMEN

The functionality of a 3422-base pair promoter fragment from the mouse alpha(1B)-adrenergic receptor (alpha(1B)AR) gene was examined. This fragment, cloned from a mouse genomic library, was found to have significant sequence homology to the known human and rat alpha(1B)AR promoters. However, the consensus motif of several key cis-acting elements is not conserved among the rat, human, and mouse genes, suggesting species specificity. Confirming fidelity of the murine promoter, robust in vitro expression of a chloramphenicol acetyltransferase (CAT) reporter was detected in known alpha(1B)AR-expressing BC(3)H1, NB41A3, and DDT(1)MF-2 cells transiently transfected with a promoter-CAT construct. Conversely, minimal CAT expression was detected in known alpha(1B)AR-negative RAT-1 and R3T3 cells. These findings were extended by transfecting the same promoter-CAT construct into various primary cell types. In support of the hypothesis that alpha(1)ARs are differentially expressed in the smooth muscle of the vasculature, primary cultures of superior mesenteric and renal artery vascular smooth muscle cells showed significantly stronger CAT expression than did vascular smooth muscle cells derived from pulmonary, femoral, and iliac arteries. Primary osteoblastic bone-forming cells, which are known to be alpha(1B)AR negative, showed minimal CAT expression. Indicating regulatory function through cis-acting elements, RAT-1, R3T3, NB41A3, BC(3)H1, and DDT(1)MF2 cells transfected with the promoter-CAT construct all showed increased CAT production when challenged with forskolin or hypoxic conditions. Additionally, tissue-specific regulation of the promoter was observed when cells were simultaneously challenged with both forskolin and hypoxia. These results collectively demonstrate that a 3.4-kb PvuII fragment of the murine alpha(1B)AR gene promoter can: 1) drive tissue-specific production of a CAT reporter in both clonal and primary cell lines; and 2) confer tissue-specific regulation of that CAT reporter when induced by challenge with forskolin and/or hypoxic conditions.

Asunto(s)

Regiones Promotoras Genéticas , Receptores Adrenérgicos alfa 1/genética , Células 3T3 , Animales , Secuencia de Bases , Hipoxia de la Célula , Línea Celular , Células Cultivadas , Clonación de Organismos , AMP Cíclico/fisiología , Femenino , Regulación de la Expresión Génica , Genes Reporteros , Humanos , Ratones , Datos de Secuencia Molecular , Músculo Liso Vascular/fisiología , Ratas , Receptores Adrenérgicos alfa 1/metabolismo , Homología de Secuencia de Ácido Nucleico

RESUMEN

Previous work has shown that the genes encoding each alpha1-adrenoceptor subtype are coexpressed throughout the peripheral vascular system. We have evaluated subtype-selective antibodies as tools to determine the extent of protein expression in arteries. The alpha1A-, alpha1B-, and alpha1D-adrenoceptors were detected in the medial layer of the aorta, caudal, femoral, iliac, renal, superior mesenteric, and mesenteric resistance arteries. In Rat1 fibroblasts expressing each subtype, immunoreactivity was noted both on the cell surface and in a perinuclear orientation. Intense alpha1B-adrenoceptor immunostaining was similarly localized in cultured femoral and renal vascular smooth muscle cells. Although the cellular localization appeared to be the same, immunoreactivity obtained with alpha1A- and alpha1D-adrenoceptors was much less intense than that with the alpha1B-adrenoceptor. The alpha1A-adrenoceptor selective agonist A-61603 was 22-fold more potent in activating renal artery contraction when compared with the femoral artery. The expression of each alpha1-adrenoceptor was significantly decreased by in vivo application of antisense oligonucleotides targeted against each subtype. Inhibition of the expression of only one, the alpha1A in renal and the alpha1D in femoral arteries, reduced the contractile response to naphazoline. The results show: 1) subtype-selective antibodies can be used in tissues and cell culture to localize the alpha1-adrenoceptor subtypes, 2) in addition to expression on the cell surface, the alpha1-adrenoceptors are expressed intracellularly, and 3) despite expression of all adrenoceptors, a single subtype mediates the contractile response in the femoral and renal arteries.

Asunto(s)

Músculo Liso Vascular/metabolismo , Receptores Adrenérgicos alfa 1/biosíntesis , Agonistas alfa-Adrenérgicos/farmacología , Animales , Especificidad de Anticuerpos , Células Cultivadas , Arteria Femoral/citología , Arteria Femoral/efectos de los fármacos , Arteria Femoral/metabolismo , Inmunohistoquímica , Masculino , Microscopía Confocal , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Músculo Liso Vascular/citología , Músculo Liso Vascular/efectos de los fármacos , Nafazolina/farmacología , Oligonucleótidos Antisentido/farmacología , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa 1/inmunología , Receptores Adrenérgicos alfa 1/fisiología , Arteria Renal/citología , Arteria Renal/efectos de los fármacos , Arteria Renal/metabolismo

RESUMEN

Alpha 1-adrenergic receptor (AR) activation is thought to be initiated by disruption of a constraining interhelical salt bridge (). Disruption of this salt bridge is achieved through a competition for the aspartic acid residue in transmembrane domain three by the protonated amine of the endogenous ligand norepinephrine and a lysine residue in transmembrane domain seven. To further test this hypothesis, we investigated the possibility that a simple amine could mimic an important functional group of the endogenous ligand and break this alpha 1-AR ionic constraint leading to agonism. Triethylamine (TEA) was able to generate concentration-dependent increases of soluble inositol phosphates in COS-1 cells transiently transfected with the hamster alpha 1b-AR and in Rat-1 fibroblasts stably transfected with the human alpha 1a-AR subtype. TEA was also able to synergistically potentiate the second messenger production by weak partial alpha 1-AR agonists and this effect was fully inhibited by the alpha 1-AR antagonist prazosin. However, this synergistic potentiation was not observed for full alpha 1-AR agonists. Instead, TEA caused a parallel rightward shift of the dose-response curve, consistent with the properties of competitive antagonism. TEA specifically bound to a single population of alpha 1-ARs with a Ki of 28.7 +/- 4.7 mM. In addition, the site of binding by TEA to the alpha 1-AR is at the conserved aspartic acid residue in transmembrane domain three, which is part of the constraining salt bridge. These results indicate a direct interaction of TEA in the receptor agonist binding pocket that leads to a disruption of the constraining salt bridge, thereby initiating alpha 1-AR activation.

Asunto(s)

Agonistas de Receptores Adrenérgicos alfa 1 , Etilaminas/farmacología , Receptores Adrenérgicos alfa 1/metabolismo , Cloruro de Sodio/química , Animales , Sitios de Unión/genética , Células COS , Línea Celular , Cricetinae , Sinergismo Farmacológico , Etilaminas/metabolismo , Humanos , Fosfatos de Inositol/metabolismo , Mutagénesis Sitio-Dirigida , Estructura Secundaria de Proteína , Ratas , Receptores Adrenérgicos alfa 1/química , Receptores Adrenérgicos alfa 1/genética , Cloruro de Sodio/farmacología , Solubilidad , Relación Estructura-Actividad

RESUMEN

The contribution of the alpha-1B adrenergic receptor (AR) to vascular smooth muscle contraction has been assessed using a combination of immunological, molecular biological and pharmacological approaches. A subtype-selective antibody detected alpha-1B immunoreactivity in the medial layer of the aorta, caudal, femoral, iliac, mesenteric resistance, renal and superior mesenteric arteries. Receptor protection assays and antisense oligonucleotides were used to assess the contribution of the alpha-1B AR to contraction. The alpha-1B AR was implicated in mediating the phenylephrine-induced contraction of the mesenteric resistance artery. The alpha-1D AR was implicated in mediating the contraction of the aorta, femoral, iliac and superior mesenteric arteries. Similarly, the alpha-1A AR was implicated in mediating contraction of the caudal and renal arteries. In vivo application of antisense oligonucleotides targeted to the translational start site of the alpha-1B AR had no effect on the phenylephrine-induced contraction of the femoral or renal arteries. In contrast, antisense oligonucleotides directed against the alpha-1D AR significantly inhibited the phenylephrine response in the femoral artery but had no effect on the renal artery. Application of alpha-1A AR antisense oligonucleotides inhibited the contraction of the renal artery without effect on the femoral artery. These data show that (1) alpha-1B AR immunoreactivity is widely distributed in the same peripheral arteries in which previous studies detected its mRNA, and (2) despite this distribution, receptor protection and antisense oligonucleotide studies indicate that the alpha-1B AR mediates the contraction of only the mesenteric resistance artery.

Asunto(s)

Músculo Liso Vascular/fisiología , Oligonucleótidos Antisentido/farmacología , Receptores Adrenérgicos alfa 1/análisis , Vasoconstricción , Animales , Inmunohistoquímica , Masculino , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa 1/genética , Receptores Adrenérgicos alfa 1/fisiología

RESUMEN

This review is intended to discuss recent developments in the molecular pharmacology of the alpha 1-adrenergic receptor (alpha 1-AR) subtypes. After a brief historical development, we will focus on the more contemporary issues having to do with this receptor family. Emphasis will be put on recent data regarding the cloning, nomenclature, signalling mechanisms, and genomic organization of the alpha 1-AR subtypes. We will also highlight recent mutational studies that identify key amino acid residues involved in ligand binding, as well as the role of the alpha 1-AR subtypes in regulating physiologic processes.

Asunto(s)

Receptores Adrenérgicos alfa 1 , Envejecimiento , Animales , Clonación Molecular , Proteínas de Unión al GTP/metabolismo , Regulación de la Expresión Génica , Humanos , Ligandos , Modelos Moleculares , ARN Mensajero , Receptores Adrenérgicos alfa 1/química , Receptores Adrenérgicos alfa 1/genética , Receptores Adrenérgicos alfa 1/metabolismo , Fracciones Subcelulares , Distribución Tisular , Transcripción Genética

RESUMEN

alpha2-Adrenergic receptors (alpha2ARs) present in the brainstem decrease blood pressure and are targets for clinically effective antihypertensive drugs. The existence of three alpha2AR subtypes, the lack of subtype-specific ligands, and the cross-reactivity of alpha2AR agonists with imidazoline receptors has precluded an understanding of the role of individual alpha2AR subtypes in the hypotensive response. Gene targeting was used to introduce a point mutation into the alpha2aAR subtype in the mouse genome. The hypotensive response to alpha2AR agonists was lost in the mutant mice, demonstrating that the alpha2aAR subtype plays a principal role in this response.

Asunto(s)

Presión Sanguínea/fisiología , Receptores Adrenérgicos alfa 2/fisiología , Agonistas de Receptores Adrenérgicos alfa 2 , Agonistas alfa-Adrenérgicos/farmacología , Animales , Antihipertensivos/farmacología , Secuencia de Bases , Presión Sanguínea/efectos de los fármacos , Tronco Encefálico/fisiología , Tartrato de Brimonidina , Marcación de Gen , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Imidazoles/farmacología , Medetomidina , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Mutación Puntual , Quinoxalinas/farmacología , Receptores Adrenérgicos alfa 2/genética , Receptores Adrenérgicos alfa 2/metabolismo

Asunto(s)

Receptores Adrenérgicos alfa/química , Receptores Adrenérgicos alfa/fisiología , Secuencia de Aminoácidos , Animales , Humanos , Datos de Secuencia Molecular , Estructura Molecular , ARN Mensajero/metabolismo , Receptores Adrenérgicos alfa/genética , Transducción de Señal

RESUMEN

This manuscript is intended to provide a comprehensive review of the alpha-adrenoceptors (ARs) and their role in vascular regulation. The historical development of the concept of receptors and the division of the alpha-ARs into alpha 1 and alpha 2 subtypes is traced. Emphasis will be placed on current understanding of the specific contribution of discrete alpha 1- and alpha 2-AR subtypes in the regulation of the vasculature, selective agonists and antagonists for these receptors, the second messengers utilized by these receptors, the myoplasmic calcium pathways activated to initiate smooth muscle contraction, as well as the clinical uses of agonists and antagonists that work at these receptors. New information is presented that deals with the molecular aspects of ligand interactions with specific subdomains of these receptors, as well as mRNA distribution and the regulation of alpha 1- and alpha 2-AR gene transcription and translation.

Asunto(s)

Músculo Liso Vascular/fisiología , Receptores Adrenérgicos alfa/fisiología , Clonación Molecular , Proteínas de Unión al GTP/metabolismo , Humanos , Tono Muscular , Músculo Liso Vascular/efectos de los fármacos , Unión Proteica , Receptores Adrenérgicos alfa/clasificación , Receptores Adrenérgicos alfa/efectos de los fármacos , Receptores Adrenérgicos alfa/genética , Receptores Adrenérgicos alfa/metabolismo , Sistemas de Mensajero Secundario , Transducción de Señal

RESUMEN

With a selective antagonist, the specific contribution of the alpha-1D adrenoceptor (AR) to vascular smooth muscle contraction has been assessed. BMY 7378 bound to membranes expressing the cloned rat alpha-1D AR with a > 100-fold higher affinity (K1 = 2 nM) than binding to either the cloned rat alpha-1A AR (Ki = 800 nM) or the hamster alpha-1B AR (Ki = 600 nM). BMY 7378 exhibited differential potency in inhibiting vascular smooth muscle contraction. In the rat aorta and iliac artery, BMY 7378 was a high-affinity antagonist, producing parallel shifts in the phenylephrine concentration-response curve. The dissociation constants for this compound by Schild analysis were 0.95 and 4 nM for the aorta and iliac artery, respectively. The slopes of these Schild plots were not significantly different from unity. BMY 7378 was a weak antagonist in the rat caudal, mesenteric resistance and renal arteries, with Schild slopes significantly < 1. With ribonuclease protection assays, alpha-1D mRNA was found in all blood vessels examined. These data suggest that (1) BMY 7378 is a selective alpha-1D AR antagonist that can be used in functional systems to assess the contribution of this receptor in vascular smooth muscle contraction; (2) the alpha-1D AR appears to play a major role in the contraction of the aorta and iliac artery; (3) despite the fact that the mRNA for the alpha-1D AR can be detected in the caudal, mesenteric resistance (4) and renal arteries, it does not appear to play a role in mediating contraction of these blood vessels; and (4) expression of alpha-1D mRNA in a particular artery does not ensure that this receptor is involved in regulating the contraction of that artery.

Asunto(s)

Músculo Liso Vascular/fisiología , Receptores Adrenérgicos alfa 1/fisiología , Animales , Arterias/efectos de los fármacos , Arterias/metabolismo , Arterias/fisiología , Clonación Molecular , Cricetinae , Técnicas In Vitro , Masculino , Contracción Muscular/fisiología , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso Vascular/metabolismo , Piperazinas/metabolismo , Piperazinas/farmacología , Unión Proteica , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa 1/genética , Receptores Adrenérgicos alfa 1/metabolismo

RESUMEN

Three alpha 1-adrenergic receptors (ARs) have been cloned, i.e., the alpha 1B-, alpha 1C-, and alpha 1D-ARs. Compared with the alpha 1B subtype, the alpha 1A subtype in tissue is described as being insensitive to chloroethylclonidine and sensitive to SZL-49 and having a 10-100-fold higher affinity for a number of agonists and antagonists. The alpha 1A subtype is also expressed in a variety of rat tissues (as assessed by pharmacology), with greatest abundance in the cerebral cortex, hippocampus, vas deferens, and submaxillary gland. The cloned bovine alpha 1C-AR, though having an alpha 1A-AR pharmacology, was first reported as not being expressed in any rat tissue (as determined by Northern analysis) and was therefore designated as a new subtype. We report the cloning, expression, and characterization of the rat homolog of the bovine alpha 1C-AR. Using a human alpha 1C-AR probe obtained by polymerase chain reaction screening of a neuroblastoma cell line (SK-N-MC), both exon 1 and exon 2 of the rat alpha 1C-AR gene were cloned from a rat genomic library. These two exons were spliced together and cloned into the expression vector pMT2'. Transfection into COS-1 cells and analysis of the ligand-binding profile of the expressed protein receptor using 125I-HEAT revealed a 10-100-fold higher affinity for the alpha 1-AR antagonists 5-methylurapidil, (+)-niguldipine, WB-4101, and phentolamine and the agonists oxymetazoline and methoxamine, compared with the alpha 1B-AR. This ligand-binding profile is similar to that for endogenously expressed tissue alpha 1A-ARs. In addition, the rat alpha 1C-AR was the least sensitive of the three cloned subtypes to the alkylating effects of chloroethylclonidine but was the most sensitive to the alkylating prazosin analog SZL-49, properties also observed for the tissue alpha 1A subtype. Furthermore, by three different techniques, i.e., RNase protection assays, reverse transcription-polymerase chain reaction Northern blotting, and in situ hybridization histochemistry, the rat alpha 1C-AR mRNA was localized to alpha 1A-AR-rich tissues, such as rat vas deferens, hippocampus, aorta, and submaxillary gland. Taken together, these data suggest that this receptor may actually represent the alpha 1A subtype.

Asunto(s)

Receptores Adrenérgicos alfa 1/clasificación , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Northern Blotting , Bovinos , Línea Celular , Clonación Molecular , Exones , Humanos , Hibridación in Situ , Intrones , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , ARN Mensajero/análisis , Ratas , Receptores Adrenérgicos alfa 1/genética , Receptores Adrenérgicos alfa 1/metabolismo , Proteínas Recombinantes/biosíntesis , Homología de Secuencia de Aminoácido , Distribución Tisular

RESUMEN

In situ hybridization histochemistry, radioligand binding, and in vitro contractile studies were used to characterize the vascular distribution of the recently discovered alpha 1D-adrenoceptor. In situ hybridization with an antisense probe localized the mRNA for the alpha 1D-adrenoceptor to the medial layer of the rat aorta renal and mesenteric resistance arteries. If the tissues were first treated with RNase or a sense probe was used, no specific hybridization signal was detected. The extent to which this receptor was expressed as protein was assessed with radioligand binding studies. A series of ligands used to characterize alpha 1-adrenoceptors interacted with two sites labeled by [3H]prazosin in homogenates from the aorta and mesenteric vascular bed. The high affinity site had the characteristics of an alpha 1A-adrenoceptor. However, the low affinity site had ligand binding characteristics distinct from those of the alpha 1D-adrenoceptor or any other known alpha 1-adrenoceptor subtype. mRNA for the alpha 1B- and alpha 1C-adrenoceptors was also detected in the aorta, renal arteries, and mesenteric resistance arteries. Chloroethylclonidine (CEC) (1 and 10 microM) had differential effects on phenylephrine-induced contractions of vascular smooth muscle. CEC completely inhibited the response in the aorta and caused a partial inhibition in the mesenteric resistance artery. The same concentrations of CEC had little effect on phenylephrine responses in the renal artery. The data suggest the following. 1) mRNA for the novel alpha 1D-adrenoceptor is localized in vascular smooth muscle. 2) Definitive identification of expression of this receptor was not possible; this may be related to coexpression of other subtypes of alpha 1-adrenoceptors. 3) mRNA for the alpha 1C-adrenoceptor was detected in rat peripheral vasculature. 4) The alpha 1A-adrenoceptor is also localized in the vasculature. 5) Three and possibly four alpha 1-adrenoceptors participate in vascular smooth muscle regulation.

Asunto(s)

Músculo Liso Vascular/metabolismo , ARN Mensajero/metabolismo , Receptores Adrenérgicos alfa 1/genética , Antagonistas de Receptores Adrenérgicos alfa 1 , Antagonistas Adrenérgicos alfa/farmacología , Animales , Clonidina/análogos & derivados , Clonidina/farmacología , Hibridación in Situ , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Músculo Liso Vascular/fisiología , Fenilefrina/farmacología , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley

RESUMEN

The role of alpha-1 adrenoceptors sensitive and resistant to chloroethylclonidine (CEC) in the regulation of peripheral hemodynamics in the conscious rat has been examined. CEC treatment (15, 25 or 30 mg/kg i.p.) resulted in a sustained decrease in systemic arterial blood pressure and heart rate. These same concentrations reduced, but did not eliminate, [3H]prazosin binding sites in vascular smooth muscle homogenates. The effect of CEC administration on blood flow and regional vascular resistance was assessed using pulsed-Doppler flow probes implanted around the superior mesenteric and iliac arteries. CEC treatment resulted in a significant decrease in mesenteric and hindlimb resistance. Prazosin (3 or 5 mg/kg) reduced systemic arterial blood pressure and vascular resistance to a greater degree than did CEC. The dose-response curve for phenylephrine-induced increases in mesenteric or hindlimb vascular resistance was shifted only 2- to 10-fold to the right by CEC. Prazosin, by contrast, shifted the phenylephrine dose-response curve over 100-fold to the right. These data indicate that multiple alpha-1 adrenoceptor subtypes, both CEC sensitive and insensitive, participate in the regulation of blood flow to the gut and the hindlimb. Finally, CEC sensitive sites do not appear to play as prominent a role as insensitive sites in mediating the pressor response to phenylephrine.

Asunto(s)

Hemodinámica/fisiología , Receptores Adrenérgicos alfa 1/fisiología , Animales , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Clonidina/análogos & derivados , Clonidina/farmacología , Estado de Conciencia , Resistencia a Medicamentos , Hemodinámica/efectos de los fármacos , Miembro Posterior/irrigación sanguínea , Masculino , Arterias Mesentéricas/efectos de los fármacos , Arterias Mesentéricas/fisiología , Fenilefrina/antagonistas & inhibidores , Fenilefrina/farmacología , Prazosina/farmacología , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa 1/efectos de los fármacos , Sensibilidad y Especificidad , Resistencia Vascular/efectos de los fármacos , Resistencia Vascular/fisiología

RESUMEN

The effect of chlorethylclonidine (CEC) on arterial blood pressure and heart rate (HR) has been evaluated in the conscious rat. CEC injection (25 mg/kg i.p.) caused a statistically significant decrease in mean arterial blood pressure (MAP) that was seen 24 hr after treatment. CEC also induced a decrease in HR that was maximal at 45 min but returned to pretreatment levels after 3 hr. CEC had no effect on the ability of isoproterenol to increase HR. CEC treatment had little effect on the pressor dose-response curve of either phenylephrine or BHT 920. When injected into the brain (25 mg/kg, lateral ventricle), CEC had no effect on MAP or HR. Yohimbine injected into the lateral ventricle had no effect on the response to i.p. CEC. Prazosin, used as a standard for comparison, caused a larger fall in MAP than CEC and this hypotension was associated with tachycardia and a marked shift (greater than 300-fold) in the phenylephrine pressor dose-response curve. A reactive analog of prazosin, SZL-49 [1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-bicyclo[2,2,2]octa- 2,5-diene-2-carbonyl)piperazine], had effects similar to prazosin on MAP and HR.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Presión Sanguínea/efectos de los fármacos , Clonidina/análogos & derivados , Frecuencia Cardíaca/efectos de los fármacos , Agonistas alfa-Adrenérgicos/farmacología , Animales , Azepinas/farmacología , Clonidina/farmacología , Inyecciones Intraperitoneales , Masculino , Fenilefrina/farmacología , Prazosina/farmacología , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/efectos de los fármacos

RESUMEN

alpha 1-Adrenergic receptor (alpha 1-AR) subtypes (alpha 1A and alpha 1B) play a critical role in vascular smooth muscle contraction and circulatory homeostasis. Transcripts for these guanine nucleotide-binding protein-coupled receptors are extremely low in abundance, however, and isolation of their cDNAs is difficult. We have developed a novel technique for identifying rare clones in a cDNA library, which has been used successfully to isolate a cDNA clone encoding an alpha 1D-AR. A 564-bp polymerase chain reaction product encoding a region between the third and sixth transmembrane domains of the alpha 1D-AR was first generated using rat brain mRNA as template and highly degenerate primers. The primers corresponded to those domains but contained mismatches to the alpha 1B-AR sequences. A 3-kb transcript was identified with this polymerase chain reaction probe, by Northern analysis of rat hippocampus. However, traditional plaque hybridization failed to identify a cDNA in a rat hippocampus lambda gt10 library. By solution-phase screening of virtually the entire library, a cDNA containing a 3-kb insert was identified, amplified, and purified. This insert encodes a 560-amino acid protein corresponding to the topology of guanine nucleotide-binding protein-coupled receptors. This receptor has approximately 71% amino acid identity, in the transmembrane regions, to the hamster and rat alpha 1B-ARs. Characterization of the receptor expressed in COS-7 cells, by ligand binding and photoaffinity labeling, revealed some of the characteristics of an alpha 1A-AR. However, unlike alpha 1A-ARs characterized previously in membrane preparations or in solubilized partially purified preparations, the expressed receptor could be extensively inactivated by chlorethylclonidine. In addition, it displays ligand-binding properties that are not consistent with an alpha 1A-AR. This indicates that the cDNA clone that we have isolated encodes a novel alpha 1-AR subtype, which we classify as the alpha 1D-AR.

Asunto(s)

ADN/aislamiento & purificación , Reacción en Cadena de la Polimerasa/métodos , Receptores Adrenérgicos alfa/genética , Animales , Secuencia de Bases , Southern Blotting , Bovinos , Clonación Molecular , Codón/genética , Cricetinae , ADN/genética , Biblioteca Genómica , Hipocampo/química , Hipocampo/fisiología , Cinética , Datos de Secuencia Molecular , Prazosina/metabolismo , Ratas , Receptores Adrenérgicos alfa/clasificación , Receptores Adrenérgicos alfa/metabolismo , Homología de Secuencia de Ácido Nucleico , Transcripción Genética/genética

RESUMEN

Ligand binding studies with WB 4101 revealed that the rat aorta contains both the alpha 1a- and alpha 1b-adrenoceptor subtypes. Results obtained following treatment with the irreversible antagonists phenoxybenzamine, chlorethylclonidine or SZL-49 (4-amino-6,7-dimethoxy-2-quinazolinyl-4-(2-bicyclo[2,2,2]octa-2,5- dienylcarbonyl-2-piperazine) suggest that there is a complex interaction between the alpha 1-adrenoceptor subtypes in the aorta. Chlorethylclonidine affects only the alpha 1b-adrenoceptor, whereas the predominant action of SZL-49 is on the alpha 1a-subtype. Chlorethylclonidine significantly inhibited the response to either methoxamine or phenylephrine, agents which are selective alpha 1a-adrenoceptor agonists. Following inactivation with either chlorethylclonidine or SZL-49, the response of the rat aorta to phenylephrine was only partially antagonized by either prazosin or WB 4101. SZL-49 also inhibited the response of the rat tail artery to electrical stimulation. The response of the tail artery obtained following inactivation with SZL-49 was effectively antagonized by prazosin. Phenylephrine, prazosin or WB 4101 afforded complete protection from chlorethylclonidine adrenoceptor inactivation, while these same ligands were only partially effective against SZL-49. Either SZL-49 or chlorethylclonidine significantly impaired the irreversible adrenoceptor blocking actions of phenoxybenzamine. These results suggest: (1) only the alpha 1a-adrenoceptor subtype appears to be associated with nerve terminals in the tail artery, (2) there may be a complex interaction between the alpha 1-adrenoceptor subtypes such that both receptors must be intact and functional to observe normal agonist and antagonist interactions, (3) there may be three sites of action for agonists associated with the rat aorta.

Asunto(s)

Receptores Adrenérgicos alfa/fisiología , Antagonistas Adrenérgicos alfa/farmacología , Animales , Aorta Torácica/metabolismo , Unión Competitiva , Clonidina/análogos & derivados , Clonidina/antagonistas & inhibidores , Clonidina/farmacología , Dioxanos/metabolismo , Técnicas In Vitro , Cinética , Masculino , Metoxamina/metabolismo , Músculo Liso Vascular/fisiología , Músculo Liso Vascular/ultraestructura , Fenoxibenzamina/farmacología , Fenilefrina/antagonistas & inhibidores , Prazosina/análogos & derivados , Prazosina/antagonistas & inhibidores , Prazosina/metabolismo , Prazosina/farmacología , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/clasificación

RESUMEN

The interaction of imidazolines with alpha-1 adrenoceptor subtypes sensitive and resistant to inactivation by SZL-49 and chlorethylclonidine (CEC) has been evaluated. Clonidine, oxymetazoline, phentolamine and naphazoline or the phenethylamine, phenylephrine, interacted with high- and low-affinity sites labeled by [3H]prazosin. SZL-49 (1-1000 nM) eliminated the high-affinity sites and caused a significant reduction of the low-affinity sites. CEC (1-100 microM) reduced the number of low-affinity sites, while the effect on high-affinity sites was dependent on the route of administration. In control aortic rings the dose-response curves for either clonidine or naphazoline were biphasic, consisting of high- and low-affinity components. Only the high-affinity component was blocked by prazosin. SZL-49 was more potent than CEC at inhibiting agonist-induced contraction of rat aortic rings. The agonist responses obtained after treatment with either SZL-49 or CEC were only weakly antagonized by prazosin. The combination of SZL-49 and CEC produced no greater inhibition of muscle contraction than did SZL-49 alone. These data show that 1) imidazolines interact with different affinity at sites labeled by [3H]prazosin and these sites correspond to the alpha-1a and alpha-1b adrenoceptor subtype designation; 2) imidazolines induce smooth muscle contraction by interacting at high- and low-affinity sites; 3) these low-affinity sites do not appear to have properties of an alpha-1 adrenoceptor; 4) there may be three sites of interaction for imidazolines on the aorta, the alpha-1a and alpha-1b adrenoceptors and a site that does not have alpha-1 adrenoceptor characteristics.

Asunto(s)

Antagonistas Adrenérgicos alfa/farmacología , Imidazoles/farmacología , Músculo Liso Vascular/efectos de los fármacos , Prazosina/análogos & derivados , Prazosina/metabolismo , Receptores Adrenérgicos alfa/efectos de los fármacos , Animales , Sitios de Unión , Clonidina/análogos & derivados , Clonidina/farmacología , Interacciones Farmacológicas , Imidazoles/antagonistas & inhibidores , Inyecciones Intraperitoneales , Masculino , Músculo Liso Vascular/metabolismo , Fentolamina/metabolismo , Fenilefrina/metabolismo , Prazosina/farmacología , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/clasificación

RESUMEN

The peripheral hemodynamic effects of SZL-49, a prazosin analog capable of selectively inactivating the alpha 1a-adrenoceptor subtype, was evaluated in the conscious rat. One hour after SZL-49 administration, total peripheral vascular resistance and arterial blood pressure significantly decreased and cardiac output and heart rate increased. Twenty-four hours after SZL-49, blood pressure returned to control preinjection levels while peripheral resistance remained decreased and cardiac output and heart rate were elevated. The phenylephrine dose-response curves for mean arterial blood pressure and total peripheral vascular resistance were shifted to the right but the maximal responses were not decreased. These data show that the alpha 1a receptor plays a role in the tonic maintenance of arterial blood pressure. The alpha 1b receptor appears to participate in the response to exogenously administered agonists.

Asunto(s)

Antagonistas Adrenérgicos alfa/farmacología , Hemodinámica/efectos de los fármacos , Prazosina/análogos & derivados , Receptores Adrenérgicos alfa/fisiología , Anestesia , Animales , Presión Sanguínea/efectos de los fármacos , Gasto Cardíaco/efectos de los fármacos , Clorisondamina/farmacología , Relación Dosis-Respuesta a Droga , Masculino , Fenilefrina/farmacología , Prazosina/farmacología , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/efectos de los fármacos , Resistencia Vascular/efectos de los fármacos